Should You Buy Aurora Cannabis (TSX:ACB) After Earnings?

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) recently released mixed third-quarter earnings. Is it time to buy?

| More on:
edit Jars of marijuana

Image source: Getty Images

There are few marijuana companies with a brand name as recognizable as Aurora Cannabis (TSX:ACB)(NYSE:ACB). The Edmonton-based pot grower is notoriously famous, particularly among millennials.

No wonder, then, that investors and analysts were holding their collective breaths in expectation of Aurora releasing its Q3 earnings report on Tuesday after the market closed. How did the company fare? Is now a good time to buy?

Revenues and production keep increasing

Aurora famously spent a good deal of funds increasing its production capacity. Indeed, the desire to dominate this particular aspect of the marijuana industry is partly responsible for Aurora aggressively resorting to dilutive forms of financing, much more so than most of its peers.

Aurora took a risk in doing so, but this gamble seems to be paying dividends, at least for now. During the third quarter, Aurora’s production soared by 99% compared to the previous quarter. Aurora annualized production exceeds the 150,000-kilogram mark, which is still a far cry from its estimated peak production capacity.

Aurora’s revenues are following suit. The firm reported gross revenues of $75.2 million, a 21% increase from the previous quarter and a 357% increase year over. The company’s net revenue was $65.1 million — a 20% increase from the previous quarter and a 305% increase year over year.

Interestingly enough, Aurora’s medical and recreational sales were equal, each representing about 50% of revenues. Aurora’s long-term strategy is to focus on the medical marijuana market, a higher-margin opportunity than its recreational counterpart. Cannabis oil accounted for about 20% of the firm’s sales.

The international market also brought some decent news for Aurora, with sales of $4 million coming from abroad — a 40% increase from the previous quarter. Aurora is one of the pot companies with the most significant international presence, and this figure will likely keep on rising in future quarters.

The bad

Despite making some headway, Aurora is still not profitable. The company reported an operating loss of $77.6 million (including some adjustments) and a net loss of $160.1 million. Aurora’s net loss was an improvement from the previous quarter, but a significant decrease year over year.

Red ink at the bottom of Aurora’s income statement hardly comes as a surprise to anyone. That isn’t the worst thing on its most recent earnings report. The company’s net selling price per gram did decrease by about 5%, which does not bode very well to investors.

On this front, Aurora is probably feeling the effects of the fact that the recreational marijuana market is very competitive. There are no shortages of options for consumers, which is likely dragging prices down. This (once again) highlights the importance of  alternative high-margin markets as well as having a strong worldwide presence.

Should you buy?

Overall, Aurora seems to be well on track to executing its master plan, though this particular quarter fell a bit short of expectations. As the firm’s production capacity continues to increase, and the cost to produce cannabis falls (as it did by 26% during Q3), Aurora should keep growing its revenues.

Aurora’s international presence wasn’t really felt during this quarter; though sales abroad rose by 40%, they still represented less than 10% of total sales.

In short, Aurora still has much room for growth. Top management expects the company to be profitable on an operational basis during the next quarter. Aurora’s strategic partnership with Nelson Peltz has yet to bear fruits in the form of a partnership with a big-name company.

While a lot can still go wrong, if all the chips fall in the right places, Aurora’s stock could skyrocket. No wonder the firm is increasingly getting buy ratings from various analysts, despite its astonishingly high number of outstanding shares.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Prosper Bakiny owns shares of Aurora Cannabis.

More on Cannabis Stocks

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »